2018
DOI: 10.1080/21505594.2018.1536598
|View full text |Cite
|
Sign up to set email alerts
|

Autophagy: A new strategy for host-directed therapy of tuberculosis

Abstract: Tuberculosis (TB), which is primarily caused by the major etiologic agent Mycobacterium tuberculosis (Mtb), remains a serious infectious disease worldwide. Recently, much effort has been made to develop novel/improved therapies by modulating host responses to TB (i.e., host-directed therapy). Autophagy is an intracellular catabolic process that helps maintain homeostasis or the removal of invading pathogens via a lysosomal degradation process. The activation of autophagy by diverse drugs… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

5
122
1

Year Published

2019
2019
2024
2024

Publication Types

Select...
4
3
2

Relationship

0
9

Authors

Journals

citations
Cited by 123 publications
(128 citation statements)
references
References 105 publications
5
122
1
Order By: Relevance
“…These observations are in concordance with previous reports showing that induction of autophagy can be harnessed as a host-directed therapy (HDT) either alone or in combination with first-line TB drugs (Dara et al, 2019). Despite identification of autophagy inducers, enough information is not available about the cooperative action of various known or unknown mechanisms regulated by autophagy (Paik et al, 2019). Therefore, evaluation of promising autophagy inducers as host-directed therapy either alone or in combination with first-line TB drugs will refine therapeutic interventions against TB.…”
Section: Discussionsupporting
confidence: 90%
“…These observations are in concordance with previous reports showing that induction of autophagy can be harnessed as a host-directed therapy (HDT) either alone or in combination with first-line TB drugs (Dara et al, 2019). Despite identification of autophagy inducers, enough information is not available about the cooperative action of various known or unknown mechanisms regulated by autophagy (Paik et al, 2019). Therefore, evaluation of promising autophagy inducers as host-directed therapy either alone or in combination with first-line TB drugs will refine therapeutic interventions against TB.…”
Section: Discussionsupporting
confidence: 90%
“…Host-directed therapies have emerged as a promising alternative to counter TB. Drugs targeting host defense mechanisms or processes such as vesicle trafficking can assist the host in responding appropriately to Mtb infection, thereby promoting the effectiveness of drug treatments and reducing the time required for treatment (4,5). Using an in vivo model for the early stages of TB disease we have demonstrated the importance of Dram1 for the elimination of intracellular mycobacteria and the cell fate of infected macrophages.…”
Section: Discussionmentioning
confidence: 98%
“…Mtb pathogenicity is closely related to its ability to survive in macrophages through the deployment of strategies to escape or neutralize host defenses [1]. One of these defenses is autophagy, a cellular process that allows for the capture of intracellular bacteria and their killing by lysosomes [2][3][4][5].…”
Section: Introductionmentioning
confidence: 99%
“…On the other hand, damage to the phagosomal membrane, which is triggered by the Type VII secretion system Esx-1, promotes xenophagy via the exposure of pathogen-associated molecular patterns (PAMPs) to the cytosolic sensor cGAS (cyclic GMP-AMP synthase), followed by STING signaling and the ubiquitination of damaged phagosome or via galectin recruitment onto the damaged phagosome [7,[13][14][15]. Alternatively, the xenophagy of Mtb-containing phagosomes can be achieved exogenously using pharmaceutical drugs or immunomodulators, such as cytokines [5,16]. Xenophagy requires the formation of an LC3-decorated double-membrane-bound compartment, which is called an autophagosome and engulfs the bacteria.…”
Section: Introductionmentioning
confidence: 99%